Is BPC-157 Legal in Colorado? Federal Status, State Rules, and How to Get It

Print or save as PDF

Is BPC-157 Legal in Colorado? The Short Answer

BPC-157 is not an FDA-approved drug: no approved product contains it, there is no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. It is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians [2]. FDA has not banned it by name; it is an unapproved substance, and its compounding status is set by the bulk-substance rules and the HHS draft policy described below [2].

What Is Its Federal Status?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. In July 2026 FDA's reviewers proposed that it not be added to the pharmacy bulks list, citing poor chemical characterization, little safety and immunogenicity information, and insufficient evidence for ulcerative colitis, the use FDA evaluated [1].

It sat in category 2, the group of bulk substances FDA says may carry significant safety risks, from September 2023 until April 22, 2026, then moved to a nominated-but-withdrawn table after its nominators withdrew [5][7]. Removal was not a finding of safety, and FDA's stated concerns remain: possible immunogenicity for certain routes of administration, peptide-related impurities and characterization problems, and too little information to know whether it would harm humans [5]. It is not in category 1 either. Category 1 is the group FDA generally will not act against compounders for, if conditions are met, so that policy does not cover BPC-157 [2].

On July 23, 2026 FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation. That vote is advice only, and BPC-157 has not been added to the list; adding it requires formal rulemaking [6][7].

What Did HHS Announce in October 2026?

HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy covering six peptides, BPC-157 among them, scheduled for Federal Register publication on October 30, 2026, with public comments open for 2 weeks after publication [8][7]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [8].

Those conditions for BPC-157 include BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed), a single active ingredient, a patient-specific prescription, and a label reading "This is a compounded drug product. Not for resale." [7]. The notice is a draft, is not an FDA approval, and does not put BPC-157 on any list. It says it does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it, for example if a safety signal or product quality issue appears [8][7]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [7].

Compounded drugs are not FDA-approved: FDA does not verify their safety, effectiveness or quality before they are marketed [3].

Who Oversees Pharmacies in Colorado?

State boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities, and FDA also conducts surveillance and for-cause inspections of those pharmacies [3]. The HHS draft policy would cover qualifying state-licensed pharmacies only under its listed conditions [7][8].

Safety and Sport

FDA's adverse-event search through December 4, 2025 found 3 reports, all involving injectable BPC-157, and FDA said it cannot tell whether the peptide caused them; it concluded there is insufficient clinical safety information to characterize the drug's safety profile [1]. A 2026 systematic review found 3 human studies with 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low [10].

WADA names BPC-157 in S0 (non-approved substances) and prohibits it at all times, in and out of competition; the 2026 List has been in force since January 1, 2026 [9].